MRAI · XBRL financial data

Marpai financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MRAI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	7,385	7,189	7,008	6,591*	5,418	4,656	4,037	3,988*	4,444	4,166
Revenue from contracts with customers	8,729	8,707*	7,385	7,189	7,008	—	—	—	—	—	—	—
Research and development	267	21*	7	8	7	7*	7	0*	0*	0*	—	—
General and administrative	4,986	3,239*	3,421	3,721	2,813	2,878*	2,283	2,483	2,067	4,306*	2,130	3,069
Operating income (loss)	(7,028)	(5,155)*	(4,065)	(12,273)	(3,060)	(2,688)*	(2,250)	(3,607)	(2,771)	(4,926)*	(2,484)	(3,433)
Interest expense	384	425*	398	872	620	819*	819	813	797	804*	775	1,227
Other income (expense)	130	258*	120	120	119	36*	—	—	—	—	—	—
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	—	—	—
Net income (loss)	(7,295)	(5,027)*	(4,346)	(13,026)	(3,560)	(1,156)*	(3,069)	(4,371)	(3,494)	(5,626)*	(3,183)	(4,583)
Earnings per share, basic USD per share	(0.98)	—	(0.46)	(1.23)	(0.30)	—	(0.21)	(0.28)	(0.20)	—	(0.13)	(0.18)
Earnings per share, diluted USD per share	(0.98)	—	(0.46)	(1.23)	(0.30)	—	(0.21)	(0.28)	(0.20)	—	(0.13)	(0.18)
Weighted average shares, basic thousands of shares	7,479	—	9,406	10,627	12,044	13,936*	14,771	15,503	17,300	—	24,682	25,860
Weighted average shares, diluted thousands of shares	7,479	—	9,406	10,627	12,044	13,936*	14,771	15,503	17,300	—	24,682	25,860

Balance sheet

CSV

Fiscal quarters (MRAI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	3,018	1,147	851	1,293	830	764	729	619	445	133	201	138
Accounts receivable	977	1,125	366	805	1,228	837	368	548	377	697	738	1,017
Prepaid and other current assets	961	892	1,000	967	771	759	615	590	397	408	364	327
Total current assets	16,817	17,085	16,505	17,195	14,886	11,897	12,866	10,332	12,082	10,336	10,431	9,004
Property and equipment, net	662	611	579	546	514	0	—	—	—	0	—	—
Right-of-use asset	2,520	2,373	2,311	2,253	2,192	296	281	265	251	218	206	193
Goodwill	6,035	3,018	3,018	—	—	—	—	—	—	—	—	—
Total assets	35,611	31,679	30,088	22,216	19,607	12,878	13,718	11,061	12,753	10,904	10,915	9,467
Accounts payable	3,101	4,649	3,824	3,172	3,764	3,109	2,736	3,588	4,411	3,668	5,902	5,783
Accrued liabilities	4,659	2,816	3,076	2,643	2,957	2,585	1,906	2,069	1,982	2,115	2,261	2,456
Current portion of long-term debt	—	—	—	—	—	—	2,809	2,809	2,809	8,000	8,000	2,450
Total current liabilities	20,447	20,843	20,123	18,688	18,179	18,982	19,794	19,734	22,780	25,694	27,147	23,546
Total deposits	—	—	—	5,000	—	—	—	—	—	—	—	—
Long-term debt	—	—	—	—	—	—	15,246	15,694	16,143	11,401	11,876	18,282
Lease liability, non-current	3,813	3,684	3,547	3,405	3,257	793	730	664	598	528	457	384
Total liabilities	44,853	45,117	44,584	47,878	47,165	40,587	43,922	43,428	46,099	43,467	46,160	48,358
Accumulated deficit	(71,719)	(76,746)	(81,092)	(94,118)	(97,678)	(98,834)	(101,903)	(106,274)	(109,768)	(115,394)	(118,577)	(123,160)
Total stockholders' equity	(9,242)	(13,438)	(14,496)	(25,662)	(27,558)	(27,709)	(30,204)	(32,367)	(33,346)	(32,563)	(35,245)	(38,891)
Total liabilities and equity	35,611	31,679	30,088	22,216	19,607	12,878	13,718	11,061	12,753	10,904	10,915	9,467
Common shares outstanding (cover page) thousands of shares	7,811	10,301	10,308	11,045	13,748	14,897	14,897	17,270	23,531	25,293	25,293	26,830

Cash flows

CSV

Fiscal quarters (MRAI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(7,295)	(5,027)*	(4,346)	(13,026)	(3,560)	(1,156)*	(3,069)	(4,371)	(3,494)	(5,626)*	(3,183)	(4,583)
Stock-based compensation	847*	262*	561	1,860*	365*	371*	574	469*	415*	2,156*	203	917*
Depreciation and amortization	927*	923*	951	914*	—	—	—	—	—	—	—	—
Net cash from operating activities	(6,585)*	(425)*	(3,585)	(3,120)*	(3,546)*	(4,907)*	(115)	(3,209)*	634*	(4,763)*	(477)	(4,099)*
Net cash from investing activities	9*	1,000*	—	—	—	0*	500	0*	0*	0*	—	—
Proceeds from issuing common stock	(0)*	0*	2,727	0*	1,299*	634*	—	—	2,101*	4,199*	—	—
Net cash from financing activities	0*	(1,335)*	3,705	3,563*	1,299*	2,104*	1,892	(20)*	1,601*	3,199*	160	2,040*
Net change in cash	(6,576)*	(760)*	120	—	—	—	—	—	—	—	—	—

Compare with peers

SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Marpai	138	4,166	(4,099)*	26.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
BioRestorative Therapies	3,113	23	(3,808)	25.5M	0.9 quarters	Q1 FY26 10-QMar 31, 2026
Mangoceuticals	229	69	(261)*	21.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Health Systems	1,302	1,310	(1,353)*	28.5M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Cryo Cell International	1,426	7,824	1,142*	8.1M	—	Q3 FY26 10-QAug 31, 2026
Pacific Health Care Organization	2,653	1,513	507*	12.8M	—	Q3 FY26 10-QSep 30, 2026
BioCorRx	21	88	(440)*	29.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.